# UE LifeSciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ue-lifesciences

- Industry: Medical Devices & Equipment
- Headquarters: Philadelphia, US
- Website: www.uelifesciences.com
- Total disclosed funding: $3.1M
- Latest round: Series A (Sep 14, 2015)
- Investors on record: 2

## About

UE LifeSciences Inc. is a medical technology company focused on developing non-invasive solutions for early cancer detection, striving to enhance accessibility for diverse healthcare providers globally.Founded in 2009 and headquartered in Philadelphia, US, UE LifeSciences Inc. specializes in innovative medical devices designed for early cancer detection. The company has not undergone any significant pivots in its business strategy. It was co-founded by Bhaumik Sanghvi, Matthew Campisi, and Mihir Shah, with Madhukumar K currently serving as CEO. In October 2016, UE LifeSciences raised USD 1.2 million in funding, with Capria Ventures as one of the investors. The total amount raised by the company to date is USD 1.2 million from three deals, with the latest funding round reflecting its efforts to scale operations.UE LifeSciences specializes in innovative, non-invasive medical devices aimed at enhancing early cancer detection. Their flagship offerings include iBreastExam, a portable breast cancer screening tool, and CervAIcal, a mobile colposcope for cervical cancer assessment. These tools are designed for use by community health workers and are characterized by their ease of use, requiring minimal training, and their ability to operate offline, providing instant results with high efficacy. UE LifeSciences targets a diverse client base that includes government health departments, healthcare providers, and non-governmental organizations across multiple markets, including India, Malaysia, Colombia, and South Africa. The company has successfully entered ten international markets, reflecting its commitment to reshaping early cancer detection through accessible and effective solutions.UE LifeSciences generates revenue through partnerships and direct sales of its medical devices to healthcare providers and organizations. The company’s transactions are structured around B2B arrangements, where clients purchase the iBreastExam and CervAIcal tools, enabling broader access to early cancer detection services. These devices may be sold as part of a comprehensive package that includes training and support services, enhancing their value proposition. Given the diverse healthcare settings in which these products are employed, UE LifeSciences collaborates with governments and healthcare organizations to ensure that its offerings meet local health needs effectively. The company has received USD 1.7 million in grant awards, and it has raised USD 8.5 million in capital, underscoring its financial backing and support towards scaling its operations and product distribution.UE LifeSciences plans to leverage its recent funding of USD 1.2 million, raised in October 2016, to enhance its product offerings and expand into new markets. The company aims to develop additional medical devices targeting various forms of cancer, with plans for launch within the next few years. Specifically, UE LifeSciences is focusing on expanding its presence in Asia and Latin America by 2025, aiming to establish partnerships with local health organizations to streamline access to its innovative solutions.

## Funding rounds

- Series A, Sep 14, 2015, $3M — Aarin Capital, Capria Ventures
- Seed, May 21, 2015, $0.1M — Capria Ventures

## Investors

- Capria Ventures (https://capitalatlas.ai/funds/capria-ventures) — Seed, Series A
- Aarin Capital — Series A